U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537816) titled 'Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients' on April 12.
Brief Summary: This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflamm...